Osteogenesis imperfecta (OI) is a genetic bone pathology with prenatal onset, characterized by brittle bones in response to abnormal collagen composition. There is presently no cure for OI. We previously showed that human first trimester fetal blood mesenchymal stem cells (MSCs) transplanted into a murine OI model (oim mice) improved the phenotype. However, the clinical use of fetal MSC is constrained by their limited number and low availability. In contrast, human fetal early chorionic stem cells (e-CSC) can be used without ethical restrictions and isolated in high numbers from the placenta during ongoing pregnancy. Here, we show that intraperitoneal injection of e-CSC in oim neonates reduced fractures, increased bone ductility and bone volume (BV), increased the numbers of hypertrophic chondrocytes, and upregulated endogenous genes involved in endochondral and intramembranous ossification. Exogenous cells preferentially homed to long bone epiphyses, expressed osteoblast genes, and produced collagen COL1A2. Together, our data suggest that exogenous cells decrease bone brittleness and BV by directly differentiating to osteoblasts and indirectly stimulating host chondrogenesis and osteogenesis. In conclusion, the placenta is a practical source of stem cells for the treatment of OI.
Get full access to this article
View all access options for this article.
References
1.
DalgleishR. (1997). The human type I collagen mutation database. Nucleic Acids Res, 25:181–187.
2.
Cohen-SolalL, ZylberbergL, SangalliA, Gomez LiraM and MottesM. (1994). Substitution of an aspartic acid for glycine 700 in the alpha 2(I) chain of type I collagen in a recurrent lethal type II osteogenesis imperfecta dramatically affects the mineralization of bone. J Biol Chem, 269:14751–14758.
3.
StossH and FreisingerP. (1993). Collagen fibrils of osteoid in osteogenesis imperfecta: morphometrical analysis of the fibril diameter. Am J Med Genet, 45:257
4.
Van DijkFS, PalsG, Van RijnRR, NikkelsPG and CobbenJM. (2010). Classification of osteogenesis imperfecta revisited. Eur J Med Genet, 53:1–5.
5.
LetochaAD, CintasHL, TroendleJF, ReynoldsJC, CannCE, et al. (2005). Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res, 20:977–986.
6.
WardLM, RauchF, WhyteMP, D'AstousJ, GatesPE, et al. (2011). Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab, 96:355–364.
7.
RauchF and GlorieuxFH. (2004). Osteogenesis imperfecta. Lancet, 363:1377–1385.
8.
HorwitzEM, ProckopDJ, GordonPL, KooWW, FitzpatrickLA, et al. (2001). Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood, 97:1227–1231.
9.
HorwitzEM, GordonPL, KooWK, MarxJC, NeelMD, et al. (2002). Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA, 99:8932–8937.
10.
Le BlancK, GotherstromC, RingdenO, HassanM, McMahonR, et al. (2005). Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation, 79:1607–1614.
11.
PereiraRF, O'HaraMD, LaptevAV, HalfordKW, PollardMD, et al. (1998). Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci USA, 95:1142–1147.
12.
PanaroniC, GioiaR, LupiA, BesioR, GoldsteinSA, et al. (2009). In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta. Blood, 114:459–468.
13.
WangX, LiF and NiyibiziC. (2006). Progenitors systemically transplanted into neonatal mice localize to areas of active bone formation in vivo: implications of cell therapy for skeletal diseases. Stem Cells, 24:1869–1878.
14.
LiF, WangX and NiyibiziC. (2007). Distribution of single-cell expanded marrow derived progenitors in a developing mouse model of osteogenesis imperfecta following systemic transplantation. Stem Cells, 25:3183–3193.
15.
GuillotPV, AbassO, BassettJH, ShefelbineSJ, Bou-GhariosG, et al. (2008). Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood, 111:1717–1725.
16.
VanleeneM, SaldanhaZ, CloydKL, JellG, Bou-GhariosG, et al. (2011). Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties. Blood, 117:1053–1060.
17.
Portmann-LanzCB, SchoeberleinA, HuberA, SagerR, MalekA, et al. (2006). Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol, 194:664–673.
18.
PoloniA, RosiniV, MondiniE, MauriziG, ManciniS, et al. (2008). Characterization and expansion of mesenchymal progenitor cells from first-trimester chorionic villi of human placenta. Cytotherapy, 10:690–697.
19.
BarlowS, BrookeG, ChatterjeeK, PriceG, PelekanosR, et al. (2008). Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev, 17:1095–1107.
20.
SonciniM, VertuaE, GibelliL, ZorziF, DenegriM, et al. (2007). Isolation and characterization of mesenchymal cells from human fetal membranes. J Tissue Eng Regen Med, 1:296–305.
21.
LiCD, ZhangWY, LiHL, JiangXX, ZhangY, et al. (2005). Isolation and identification of a multilineage potential mesenchymal cell from human placenta. Placenta [Epub ahead of print]; DOI: 10.1016/j.placenta.2005.08.003.
22.
YenBL, HuangHI, ChienCC, JuiHY, KoBS, et al. (2005). Isolation of multipotent cells from human term placenta. Stem Cells, 23:3–9.
23.
JonesGN, MoschidouD, Puga-IglesiasTI, KuleszewiczK, VanleeneM, et al. (2012). Ontological differences in first compared to third trimester human fetal placental chorionic stem cells. PLoS One, 7:e43395
24.
GuillotPV, GotherstromC, ChanJ, KurataH, FiskNM. (2007). Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells, 25:646–654.
25.
BassettJH, BoydeA, HowellPG, BassettRH, GallifordTM, et al. (2010). Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. Proc Natl Acad Sci USA, 107:7604–7609.
26.
ChappardD, PalleS, AlexandreC, VicoL and RiffatG. (1987). Bone embedding in pure methyl methacrylate at low temperature preserves enzyme activities. Acta Histochem, 81:183–190.
27.
YongchangY and WangY. (2013). ATDC5: An excellent in vitro model cell line for skeletal development. J Cell Biochem, 114:1223–1229.
28.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
29.
AdewumiO, AflatoonianB, Ahrlund-RichterL, AmitM, AndrewsPW, et al. (2007). Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol, 25:803–816.
30.
SkottmanH, MikkolaM, LundinK, OlssonC, StrombergAM, et al. (2005). Gene expression signatures of seven individual human embryonic stem cell lines. Stem Cells, 23:1343–1356.
31.
GotherstromC, RingdenO, TammikC, ZetterbergE, WestgrenM, et al. (2004). Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol, 190:239–245.
32.
McKeeMD and NanciA. (1996). Osteopontin: an interfacial extracellular matrix protein in mineralized tissues. Connect Tissue Res, 35:197–205.
33.
LianJB, SteinGS, StewartC, PuchaczE, MackowiakS, et al. (1989). Osteocalcin: characterization and regulated expression of the rat gene. Connect Tissue Res, 21:61–68; discussion 69.
34.
RyooHM, HoffmannHM, BeumerT, FrenkelB, TowlerDA, et al. (1997). Stage-specific expression of Dlx-5 during osteoblast differentiation: involvement in regulation of osteocalcin gene expression. Mol Endocrinol, 11:1681–1694.
35.
ChipmanSD, SweetHO, McBrideDJJr., DavissonMT, MarksSCJr., et al. (1993). Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Proc Natl Acad Sci USA, 90:1701–1705.
36.
JamesCG, StantonLA, AgostonH, UliciV, UnderhillTM, et al. (2010). Genome-wide analyses of gene expression during mouse endochondral ossification. PLoS One, 5:e8693
37.
Haleem-SmithH, CalderonR, SongY, TuanRS and ChenFH. (2012). Cartilage oligomeric matrix protein enhances matrix assembly during chondrogenesis of human mesenchymal stem cells. J Cell Biochem, 113:1245–1252.
38.
BiW, DengJM, ZhangZ, BehringerRR and de CrombruggheB. (1999). Sox9 is required for cartilage formation. Nat Genet, 22:85–89.
39.
BellDM, LeungKK, WheatleySC, NgLJ, ZhouS, et al. (1997). SOX9 directly regulates the type-II collagen gene. Nat Genet, 16:174–178.
40.
LefebvreV, HuangW, HarleyVR, GoodfellowPN and de CrombruggheB. (1997). SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. Mol Cell Biol, 17:2336–2346.
41.
TsujiY, ShimadaY, TakeshitaT, KajimuraN, NomuraS, et al. (2000). Cryptic dimer interface and domain organization of the extracellular region of metabotropic glutamate receptor subtype 1. J Biol Chem, 275:28144–28151.
42.
MuirH. (1995). The chondrocyte, architect of cartilage. Biomechanics, structure, function and molecular biology of cartilage matrix macromolecules. Bioessays, 17:1039–1048.
43.
AmanoK, HataK, SugitaA, TakigawaY, OnoK, et al. (2009). Sox9 family members negatively regulate maturation and calcification of chondrocytes through up-regulation of parathyroid hormone-related protein. Mol Biol Cell, 20:4541–4551.
44.
HuangW, ChungUI, KronenbergHM and de CrombruggheB. (2001). The chondrogenic transcription factor Sox9 is a target of signaling by the parathyroid hormone-related peptide in the growth plate of endochondral bones. Proc Natl Acad Sci USA, 98:160–165.
45.
HuangW, ZhouX, LefebvreB and de CrombruggheV. (2000). Phosphorylation of SOX9 by cyclic AMP-dependent protein kinase A enhances SOX9's ability to transactivate a Col2a1 chondrocyte-specific enhancer. Mol Cell Biol, 20:4149–4158.
46.
FergusonCM, SchwarzEM, ReynoldsPR, PuzasJE, RosierRN, et al. (2000). Smad2 and 3 mediate transforming growth factor-beta1-induced inhibition of chondrocyte maturation. Endocrinology, 141:4728–4735.
47.
AriasJL, NakamuraO, FernandezMS, WuJJ, KniggeP, et al. (1997). Role of type X collagen on experimental mineralization of eggshell membranes. Connect Tissue Res, 36:21–33.
48.
MartinA, LiuS, DavidV, LiH, KarydisA, et al. (2011). Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J, 25:2551–2562.
49.
Lorenz-DepiereuxB, BastepeM, Benet-PagesA, AmyereM, WagenstallerJ, et al. (2006). DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet, 38:1248–1250.
50.
WangX, HarimotoK, XieS, ChengH, LiuJ, et al. (2010). Matrix protein biglycan induces osteoblast differentiation through extracellular signal-regulated kinase and Smad pathways. Biol Pharm Bull, 33:1891–1897.
51.
ChristiansenHE, SchwarzeU, PyottSM, Al SwaidA, Al BalwiM, et al. (2010). Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet, 86:389–398.
52.
StaceyA, BatemanJ, ChoiT, MascaraT, ColeW, et al. (1988). Perinatal lethal osteogenesis imperfecta in transgenic mice bearing an engineered mutant pro-alpha 1(I) collagen gene. Nature, 332:131–136.
53.
DucyP, ZhangR, GeoffroyV, RidallAL and KarsentyG. (1997). Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell, 89:747–754.
54.
KomoriT, YagiH, NomuraS, YamaguchiA, SasakiK, et al. (1997). Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 89:755–764.
55.
OttoF, ThornellAP, CromptonT, DenzelA, GilmourKC, et al. (1997). Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell, 89:765–771.
56.
KarsentyG and WagnerEF. (2002). Reaching a genetic and molecular understanding of skeletal development. Dev Cell, 2:389–406.
57.
KurataH, GuillotPV, ChanJ and FiskNM. (2007). Osterix induces osteogenic gene expression but not differentiation in primary human fetal mesenchymal stem cells. Tissue Eng, 13:1513–1523.
58.
GiustinaA, MazziottiG and CanalisE. (2008). Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev, 29:535–559.
59.
MochizukiH, HakedaY, WakatsukiN, UsuiN, AkashiS, et al. (1992). Insulin-like growth factor-I supports formation and activation of osteoclasts. Endocrinology, 131:1075–1080.
60.
NiuT and RosenCJ. (2005). The insulin-like growth factor-I gene and osteoporosis: a critical appraisal. Gene, 361:38–56.
61.
YakarS, RosenCJ, BeamerWG, Ackert-BicknellCL, WuY, et al. (2002). Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest, 110:771–781.
62.
JonesGN, MoschidouD, LayK, AbdulrazzakH, VanleeneM, et al. (2012). Upregulating CXCR4 in human fetal mesenchymal stem cells enhances engraftment and bone mechanics in a mouse model of osteogenesis imperfecta. Stem Cells Transl Med, 1:70–78.
63.
Granero-MoltoF, WeisJA, MigaMI, LandisB, MyersTJ, et al. (2009). Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells, 27:1887–1898.
64.
LiH, JiangX, DelaneyJ, FranceschettiT, Bilic-CurcicI, et al. (2010). Immature osteoblast lineage cells increase osteoclastogenesis in osteogenesis imperfecta murine. Am J Pathol, 176:2405–2413.
65.
KalajzicI, TerzicJ, RumboldtZ, MackK, NaprtaA, et al. (2002). Osteoblastic response to the defective matrix in the osteogenesis imperfecta murine (oim) mouse. Endocrinology, 143:1594–1601.
66.
ZhouY, FanW, PrasadamI, CrawfordR and XiaoY. (2012). Implantation of osteogenic differentiated donor mesenchymal stem cells causes recruitment of host cells. J Tissue Eng Regen Med.
67.
LiX, LingW, PennisiA, WangY, KhanS, et al. (2011). Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells, 29:263–273.
68.
ZhengQ, ZhouG, MorelloR, ChenY, Garcia-RojasX, et al. (2003). Type X collagen gene regulation by Runx2 contributes directly to its hypertrophic chondrocyte-specific expression in vivo. J Cell Biol, 162:833–842.
69.
OtsuruS, GordonPL, ShimonoK, JethvaR, MarinoR, et al. (2012). Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood, 120:1933–1941.
70.
ZebazeRM, JonesAC, PandyMG, KnackstedtMA and SeemanE. (2011). Differences in the degree of bone tissue mineralization account for little of the differences in tissue elastic properties. Bone, 48:1246–1251.
71.
GuptaHS, SchratterS, TeschW, RoschgerP, BerzlanovichA, et al. (2005). Two different correlations between nanoindentation modulus and mineral content in the bone-cartilage interface. J Struct Biol, 149:138–148.
72.
VanleeneM, PorterA, GuillotPV, BoydeA, OyenM, et al. (2012). Ultra-structural defects cause low bone matrix stiffness despite high mineralization in osteogenesis imperfecta mice. Bone, 50:1317–1323.
73.
FrayssinetP, JouveJL and Viehweger.E (2004). Cartilage cells. In: Biomechanics and Biomaterials in Orthopaedics. ThorngrenKG, PoitoutDG, KotzR, eds. Springer, London, pp 219.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
